0.03
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Firebrick Pharma
Its shares trade on ASX under the ticker FRE.AX. It has been listed since 28 January 2022. In the fiscal year to 30 June 2026, it reported revenue of A$106,029 and a net loss of A$3.1m. At that date it held total assets of A$2.2m and shareholders' equity of A$1.7m.
Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company is headquartered in Melbourne, Victoria. The company went IPO on 2022-01-28. The firm is engaged in developing and commercializing a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The company also has a third patent family covering the Nasodine formulation. The company is completing two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals. Positive Phase 3 trial results also be important for securing regulatory approvals and partnerships in markets outside Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Jan 2022
- Website
- firebrickpharma.com ↗
Leadership
Pay as last reported
- Dr. Peter MolloyChief Executive Officer, Founder, Executive Chairman of the Board, since 2012
- Mr. Stephen Francis GoodallFounder, Chief Operating Officer, Executive Director, since 2012
- Mr. Kavi BekarmaChief Financial Officer
- Mr. Stephen BuckleyCompany Secretary
- Mr. Peter KashNon-Executive Director
- Mr. Rick LegleiterNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Firebrick Pharma Ltd. owns core patents for intranasal povidone-iodine treatment of the common cold.
- The company has a second patent family covering prevention of pandemic viral diseases including COVID-19.
- Nasodine formulation is protected by a third patent family for nasal spray treatment.
Weaknesses
- The company is completing a Phase 2 trial for Nasodine in COVID-19 treatment.
- A Phase 3 trial for Nasodine is ongoing to confirm efficacy for common cold treatment.
- Positive Phase 3 results are critical for securing regulatory approvals and partnerships.
Opportunities
- Nasodine has potential for international approvals following Phase 3 trial success.
- The company's patent portfolio supports expansion into pandemic viral disease prevention markets.
- Commercialization of Nasodine could target global cold treatment markets.
Threats
- Regulatory approvals depend on successful Phase 3 trial outcomes for Nasodine.
- Competition in the common cold treatment market remains a challenge.
- Market entry for Nasodine requires positive clinical trial results.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.